ENDRA Life Sciences (ENDRA Life Sciences) GF Value : $0.00 (As of May. 24, 2024)

View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-24), ENDRA Life Sciences's share price is $4.50. ENDRA Life Sciences's GF Value is $0.00. Therefore, ENDRA Life Sciences's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes ENDRA Life Sciences is Not Valued.

ENDRA Life Sciences (NAS:NDRAU) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

ENDRA Life Sciences's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	4.50	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENDRA Life Sciences GF Value Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRAU) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

NDRA:USA

Address

3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570

Website

https://www.endrainc.com

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Executives

Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
Anthony Digiandomenico	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Michael Milos Thornton	officer: Chief Technology Officer	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
David R. Wells	officer: Chief Financial Officer	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Francois Roger Michelon	director, officer: Chief Executive Officer	430 N. JUNO LANE, JUNO BEACH FL 33406
Michael Harsh	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Lou Basenese	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman	director	C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Sanjiv Sam Gambhir	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc	10 percent owner	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	10 percent owner	1312 CEDAR ST., SANTA MONICA CA 90405